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Abstract
Background
Numerous risk prediction algorithms based on conventional risk factors for Coronary Heart
Disease (CHD) are available but provide only modest discrimination. The inclusion of
genetic information may improve clinical utility.
Methods
We tested the use of two gene scores (GS) in the prospective second Northwick Park Heart
Study (NPHSII) of 2775 healthy UK men (284 cases), and Pakistani case-control studies
from Islamabad/Rawalpindi (321 cases/228 controls) and Lahore (414 cases/219 controls).
The 19-SNP GS included SNPs in loci identified by GWAS and candidate gene studies,
while the 13-SNP GS only included SNPs in loci identified by the CARDIoGRAMplusC4D
consortium.
Results
In NPHSII, the mean of both gene scores was higher in those who went on to develop CHD
over 13.5 years of follow-up (19-SNP p=0.01, 13-SNP p=7x10-3). In combination with the
Framingham algorithm the GSs appeared to show improvement in discrimination (increase
in area under the ROC curve, 19-SNP p=0.48, 13-SNP p=0.82) and risk classification (net
reclassification improvement (NRI), 19-SNP p=0.28, 13-SNP p=0.42) compared to the Fra-
mingham algorithm alone, but these were not statistically significant. When considering
only individuals who moved up a risk category with inclusion of the GS, the improvement in
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risk classification was statistically significant (19-SNP p=0.01, 13-SNP p=0.04). In the Paki-
stani samples, risk allele frequencies were significantly lower compared to NPHSII for 13/19
SNPs. In the Islamabad study, the mean gene score was higher in cases than controls only
for the 13-SNP GS (2.24 v 2.34, p=0.04). There was no association with CHD and either
score in the Lahore study.
Conclusion
The performance of both GSs showed potential clinical utility in European men but much
less utility in subjects from Pakistan, suggesting that a different set of risk loci or SNPs may
be required for risk prediction in the South Asian population.
Introduction
Despite being largely preventable, coronary heart disease (CHD) remains the most common
cause of the death worldwide [1, 2]. There is a growing CHD burden in the developing world
[3], particularly in South Asian countries such as Pakistan where the prevalence of CHD in
urban Karachi has approximately doubled since 1970[4]. This increase is most likely due to the
adoption of a more “Western” lifestyle combined with a greater susceptibility to metabolic syn-
drome[5]. Many CHD risk factors, such as smoking status and hypertension, can be modified
through lifestyle changes or drug therapy[6], which can greatly reduce CHDmorbidity and
mortality[7, 8]. Given that the atherosclerotic process can begin many decades before clinical
manifestation, this provides an opportunity for preventative measures to be employed to avoid
its escalation[9].
In order to target lifestyle and therapeutic intervention appropriately, those most at risk of
developing CHDmust be identified. A number of conventional risk factor (CRF) scores to
determine 10-year risk CHD risk have been developed. These include the Framingham risk
score [10], SCORE [11] and QRISK2 [12]. Individuals are then classified on the basis of the
CRF score. Until recently the cut-off for the high risk category (those who qualify for statin
treatment for primary prevention of CHD) was set at 20% ten year risk of CHD[6]. However,
lower cut-offs have been proposed in both the USA [13] and the UK, with the 2014 National
Institute for Health and Care Excellence (NICE) guidelines setting the threshold at 10%[14].
To date, such risk scores have provided only modest discrimination. Most events occur in indi-
viduals classified as being at intermediate risk [1, 15]. By improving risk prediction tools, pre-
ventative measures can be targeted more appropriately.
It is has been estimated that heritability of CHD is 40–50% [16] and more than forty CHD
associated loci have been identified using both traditional candidate gene studies and genome-
wide association studies (GWAS)[17, 18]. The most recent publication from the CARDIo-
GRAMplusC4D consortium [18] increased the number of robustly associated loci to 46. The
inclusion of genetic information is therefore a good candidate to improve CHD risk prediction.
As each variant is associated with a modest effect size, the addition of a single CHD risk variant
to a CRF score does not improve risk stratification [19–21]. However, combining even a small
number of variants into a “gene score” has been shown to improve classification or discrimina-
tion of individuals [22, 23].
The objective of this study was to determine whether the inclusion of a CHD risk gene score
has clinical utility in the European population. We sought to do this by investigating whether
addition of a gene score improves discrimination and prediction over and above the use of the
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Framingham CRF score alone in a prospective study of middle-aged men from the UK. We
then looked to determine if the same genetic variants can be used in individuals from the
Indian Subcontinent. Two gene scores, one with 19 SNPs taken from both GWAS and candi-
date gene studies and one with 13 SNPs where only SNPs in loci identified by the CARDIo-
GRAMplusC4D consortium were included, were tested.
Methods
NPHSII
NPHSII is a prospective CHD study of approximately 3000 men as described previously [2].
Briefly, middle-aged men (50–64) were recruited from 9 general practices in the UK. Anyone
with a history of CHD or diabetes was excluded. There was a median of 13.5 years follow-up.
CHD was defined as acute myocardial infarction (MI), silent MI or undergoing coronary sur-
gery. All subjects gave written informed consent and the study had ethical approval from the
national research ethics service (NRES) Committee London-Central.
Pakistani cohorts
Two case-control studies from Pakistan were collected. One group was collected from the
Rawalpindi Institute of Cardiology, Pakistan. All cases had had an MI as defined by a positive
test for troponin T, ST segment changes on electrocardiogram and typical chest pain radiating
in the chest that was not relieved at rest. This study will hereafter be referred to as the “Islama-
bad” study. The study had approval from the Institutional Review Board and Ethics Committee
of Shifa College of Medicine, Shifa International Hospital, Islamabad and all subjects gave writ-
ten informed consent. The second group were collected from hospitals in Lahore, Pakistan. All
cases had CHD as defined by echocardiogram or angiography. This study will hereafter be
referred to as the “Lahore” study. All subjects gave written informed consent and the study had
ethical approval from the institutional ethical committee, University of the Punjab, Lahore. In
both studies controls were taken from the general population.
Gene Scores
The SNPs included in the gene scores are presented in Table 1, along with the source publica-
tion(s). Each SNP was weighted by its effect size as reported in their respective publications
and the gene scores were calculated by multiplying the number of risk alleles by the natural log
of the odds ratio for each SNP and adding the products together. It was assumed that all SNPs
were acting in an additive manner apart from rs1799983, which was treated in a recessive man-
ner. A 13 SNP score was also considered using only SNPs in loci identified by the most recent
publication from the CARDIoGRAMplusC4D consortium [18].
Statistical analysis
Analysis for NPHSII was conducted using STATA v13.1[24]. Analysis for the Islamabad study
and genotype frequency comparisons between all studies were conducted using R v3.0.3 [25].
Analysis for the Lahore study was conducted using SPSS version 22.0[26]. Variables were com-
pared between the CHD and no-CHD groups using two-sided t-tests for continuous variables
and χ2 tests for categorical variables. Hardy Weinberg equilibrium was assessed using χ2 tests.
The Framingham 10-year risk score was calculated using the equations described in [10]. The
relationship between quintile of gene score and CHD was investigated using logistic regression.
CHD Risk Prediction Gene Score in UK Men and the Pakistani Population
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Results
Results from NPHSII
The baseline characteristics for the participants of NPHSII are presented in Table 2. As
expected, the men who went on to develop CHD were older, had higher BMI, higher blood
Table 1. SNPs included in the gene scores.
Gene/Locus SNP SNP Location Risk Allele Odds Ratio Reference
MIA3* rs17465637 Intergenic C 1.14 Kathiresan et al. [36]
9p21* rs10757274 Intergenic G 1.29 Kathiresan et al. [36]
DAB2IP rs7025486 Intergenic A 1.16 Harrison, Cooper [37]
CXCL12* rs1746048 Intergenic C 1.17 Kathiresan et al. [36], Samani, Erdmann [38]
ACE rs4341 Intergenic G 1.22 Casas, Cooper [17]
NOS3 rs1799983 E289D T 1.31 Casas, Cooper [17]
APOA5* rs662799 Promoter Variant G 1.19 Sarwar, Sandhu [39]
SMAD3 rs17228212 Intergenic C 1.21 Samani, Erdmann [38]
APOB* rs1042031 E4181K A 1.73 Casas, Cooper [17]
CETP rs708272 Intronic C 1.28 Casas, Cooper [17]
LPA* rs3798220 I1891M C 1.92 Clarke, Peden [40]
LPA* rs10455872 Intergenic G 1.70 Clarke, Peden [40]
MRAS* rs9818870 Intergenic T 1.15 Erdmann, Grosshennig [41]
LPL* rs328 S447X C 1.25 Casas, Cooper [17]
LPL rs1801177 D9N A 1.33 Sagoo, Tatt [42]
SORT1*+ rs646776+ Intergenic A 1.19 Kathiresan et al. [36]
PCSK9* rs11591147 R46L G 1.43 Benn, Nordestgaard [43]
APOE* rs429358 C112R C 1.06 Bennet, Di Angelantonio [44]
APOE* rs7412 C158R T++ 0.80 Bennet, Di Angelantonio [44]
SNPs marked with an asterisk (*) are included in both the 19 and 13 SNP gene score.
+rs599839 was genotyped instead of rs646776, r2 = 0.95 in Europeans
++For rs7412, the protective SNP is included in the gene score
doi:10.1371/journal.pone.0130754.t001
Table 2. Baseline Characteristics of NPHSII participants.
Trait NPHSIINo CHD(n = 2491) NPHSIICHD(n = 284) p-value
Age (years) 56.0 (3.4) 56.6 (3.5) 7x10-3
Male (%) 100 100 -
Smoking (%) 27 37.0 5x10-4
BMI (kg/m2) 26.4 (3.5) 26.9 (3.4) 0.04
Systolic Blood Pressure (mmHg) 137.9 (19.1) 142.5 (19.4) 2x10-4
Diastolic Blood Pressure (mmHg) 84.3 (11.2) 86.7 (11.4) 9x10-4
Cholesterol (mmol/l) 5.70 (1.01) 6.06 (1.02) <1x10-4
Triglyceride (mmol/l) 1.77 (0.93) 2.05 (1.06) <1x10-4
Framingham 10 year CHD risk 0.10 (0.07–0.15) 0.14 (0.09–0.20) 9x10-4
19 SNP Gene Score 3.30 (0.57) 3.42 (0.55) 0.01
13 SNP Gene Score 2.43 (0.48) 2.53 (0.45) 7x10-3
All variable are present as the mean plus standard deviation, apart from the Framingham 10 year CHD risk score where the mean and interquartile range
are given.
doi:10.1371/journal.pone.0130754.t002
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pressure, higher cholesterol, higher triglycerides and a higher proportion were smokers, at
baseline. Moreover, those who went on to develop CHD had a statistically significantly higher
10 year CHD risk as calculated using the Framingham score.
The genotype frequency of each SNP in NPHSII is shown in S1 Table. All SNPs except
rs1042031, in APOB, were in Hardy-Weinberg equilibrium. A comparison of risk allele fre-
quency in those who did and those who did not go on to develop CHD is presented in S4
Table. There was a statistically significant difference between the two groups for rs10757274 at
the 9p21 locus and rs1746048 (close to gene CXCL12), with the risk allele frequency being
higher in the CHD group for both SNPs.
The genotype information was combined using a weighted genetic risk score. For the 19
SNP GS, full data for Framingham score plus gene score was available for 1164 individuals, 114
of whom developed CHD. For the 13 SNP GS full data for Framingham score plus gene score
was available for 1437 individuals, 143 of whom developed CHD. Both gene scores were higher
in those who developed CHD during follow-up (19 SNP GS p = 0.01, 13 SNP GS p = 7x10-3).
We examined the ability of the two gene scores to reclassify those who did and those who
did not go on to develop CHD. As shown in Table 3, although more participants appeared to
be reclassified correctly with the inclusion of both the 19 SNP and 13 SNP GS compared to the
Framingham score alone, this increase was not statistically significant in either case. When
only those who were reclassified into the high risk category (set at 10% ten-year risk) were con-
sidered (those with a strong genetic predisposition to CHD with intermediate and low CRF
scores), a statistically significant number of participants were reclassified correctly (Table 3).
This was also the case when the cut-off for high risk was set at 20% (shown in S5 Table).
The predicative ability of using the Framingham CRF score was compared to the Framing-
ham score plus the genetic risk score. There was no statistically significant increase in the area
under the ROC curve for either the 19 SNP GS (p = 0.48) or the 13 SNP GS (p = 0.82) (S1 Fig).
As shown in Fig 1 and S6 Table, there was a statistically significant trend for higher quintiles
of gene score to have higher odds ratio for CHD compared to the bottom quintile for both the
19 SNP GS (p = 8x10-3) and the 13 SNP GS (p = 0.01) after adjustment for age.
Results from Pakistani studies
We then attempted to transpose these scores in two case-control samples from Pakistan. The
available conventional risk factor information for both studies is presented in Table 4. Data
was missing for up to 60% of participants for some variables in the Islamabad study. As
expected, in both studies the case group was older and had a higher proportion with diabetes,
hypertension and smokers. There was no difference in the proportion of males present in each
group. Surprisingly, in the Islamabad study, mean LDL cholesterol was not statistically
Table 3. Reclassification of NPHSII participants with the addition of the gene scores to the Framingham conventional risk factor score.
Gene
Score
CHD
Status
Framingham10 year CHD
risk
Reclassiﬁcation: Increased
Risk
Reclassiﬁcation: Decreased
Risk
Proportion Increased
Risk
19 SNP No CHD <10% 103 132 22.9%
19 SNP CHD  10% 11 9 45.8%
Overall NRI: 4.5% (-3.7%-12.7%) p = 0.28 Increased risk p = 0.01
13 SNP No CHD <10% 115 145 20.0%
13 SNP CHD  10% 13 12 34.2%
Overall NRI: 3.0% (-4.3%-10.3%) p = 0.42 Increased risk p = 0.04
NRI = net reclassiﬁcation index.
doi:10.1371/journal.pone.0130754.t003
CHD Risk Prediction Gene Score in UK Men and the Pakistani Population
PLOS ONE | DOI:10.1371/journal.pone.0130754 July 2, 2015 5 / 13
significantly different between cases and controls. This can be attributed to the treatment of
those post-MI with lipid lowering therapies. BMI, total cholesterol, triglycerides, family history
and HDL cholesterol data were available for some of the participants of the Islamabad study.
Only for HDL cholesterol was the difference between the two groups statistically significant,
being lower in the cases.
The 19 SNPs were genotyped in both Pakistani sample sets and the results are presented in
S1 Table. For the Islamabad study, five SNPs were not in Hardy-Weinberg equilibrium—MIA3
rs17465637, CXCL12 rs1746048,MRAS rs9818870, LPL rs1801177 and SMAD3
rs17228212-with an excess of homozygotes. Genotypes were confirmed by sequencing. In the
Lahore study, only one SNP–LPA rs10455872- was not in Hardy Weinberg equilibrium. The
risk allele frequencies did not differ between the two Pakistani groups as shown in Table 5. The
data from the control groups was combined and compared to that from the group in NPHSII.
Fig 1. Association between gene score and CHD in NPHSII. Logistic regression (age adjusted) was performed for each group. Error bars represent 95%
confidence intervals.
doi:10.1371/journal.pone.0130754.g001
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Table 4. Characteristics of the Pakistani sample sets.
Islamabad Lahore
Trait ControlsN = 228 CasesN = 321 p-value ControlsN = 219 CasesN = 404 p-value
Age (mean) 38(11.83) 53(11.80) <2.2x10-16 56 (10.50) 59 (12.60) 2x10-3
Gender (% Female) 34% 31% 0.52 46% 41% 0.27
BMI (kg/m2) 24.2(3.95) 24.3(4.08) 0.85 - - -
TC (mmol/l) 4.52(1.38) 4.71(3.77) 0.56 - - -
LDL-C (mmol/l) 2.66(0.78) 2.55(0.99) 0.33 2.19 (0.44) 2.74 (0.75) 6.50x10-22
HDL-C (mmol/l) 1.35(1.01) 0.96(0.22) 1.01x10-4 - - -
TG (mmol /l)* 1.44 (0.91) 1.58 (1.06) 0.22 - - -
Diabetes (%) 1 32 6.6x10-9 14 65 5.10x10-34
Hypertension (%) 15 46 4.9x10-7 16 62 9.00x10-28
Family History (%) 42 42 0.96 - - -
Smoking (%) 25 46 1.25x10-3 11 30 4.30x10-8
19 SNP Gene Score 2.89 (0.50) 2.94(0.50) 0.35 2.92(0.53) 2.93(0.50) 0.75
13 SNP Gene Score 2.24(0.42) 2.34(0.42) 0.04 2.21(0.39) 2.21(0.39) 0.95
Categorical variables were compared using a χ2 test while continuous variables were compared using Welch’s t-tests.
* Log transformed data. Geometric mean and approximate SD are given.
doi:10.1371/journal.pone.0130754.t004
Table 5. Comparison of risk allele frequencies between the control groups from the Pakistani studies and between the combined total of the Paki-
stani control groups and NPHSII.
Gene/Locus SNP RAF Islamabad Controls RAF Lahore Controls p-value RAF NPSHII(95% CI) p-value
MIA3 rs17465367 0.64(0.59–0.69) 0.63(0.58–0.67) 0.68 0.71(0.69–0.72) 3.42x10-5
9p21 rs10757274 0.44(0.40–0.49) 0.46(0.42–0.51) 0.60 0.48(0.47–0.50) 3.16x10-3
DAB2IP rs7025486 0.31 (0.26–0.35) 0.32(0.27–0.36) 0.84 0.26(0.17–0.24) 4.70x10-4
CXCL12 rs1746048 0.65 (0.61–0.70) 0.64(0.59–0.68) 0.65 0.86(0.85–0.87) <2.20x10-16
SMAD3 rs17228212 0.19 (0.15–0.22) 0.18(0.14–0.21) 0.76 0.31(0.30–0.32) 4.88x10-14
MRAS rs9818870 0.10 (0.07–0.13) 0.09(0.06–0.12) 0.75 0.16(0.15–0.17) 2.61x10-6
SORT1 rs599839 0.72 (0.68–0.77) 0.74(0.70–0.79) 0.55 0.78(0.77–0.79) 2.03x10-3
ACE rs4341 0.41 (0.36–0.45) 0.47(0.43–0.52) 0.05 0.52(0.50–0.53) 3.09x10-5
NOS3 rs1799983 0.16 (0.13–0.20) 0.18(0.15–0.22) 0.51 0.33(0.32–0.35) <2.20x10-16
APOA5 rs662799 0.15 (0.12–0.18) 0.17(0.13–0.20) 0.60 0.06(0.05–0.07) <2.20x10-16
APOB rs1042031 0.15 (0.12–0.19) 0.13(0.09–0.16) 0.24 0.18(0.17–0.19) 9.75x10-3
CETP rs708272 0.55 (0.50–0.60) 0.56(0.51–0.61) 0.83 0.56(0.55–0.58) 0.62
LPA rs3789220 0.01 (0–0.02) 0.003(0–0.01) 0.81 0.02(0.01–0.02) 0.02
LPA rs10455872 0.01 (0–0.03) 0.01(0.00–0.03) 1 0.07(0.07–0.08) 1.06x10-10
PCSK9 rs11591147 1.00 0.995 (0.00–0.01) 0.50 0.99 (0.99–0.99) 0.07
APOE rs429358 0.09 (0.06–0.11) 0.11 (0.08–0.14) 0.52 0.17 (0.16–0.18) 1.60x10-9
APOE rs7412 0.96 (0.94–0.98) 0.96 (0.94–0.98) 1 0.91 (0.90–0.92) 2.69x10-6
LPL rs328 0.92 (0.89–0.94) 0.91 (0.89–0.94) 0.98 0.90 (0.89–0.91) 0.12
LPL rs1801177 0.01 (0–0.02) 0 0.14 0.01 (0.01–0.02) 0.04
Comparisons were performed using tests of proportion. RAF = Risk Allele Frequency, CI = Conﬁdence Interval.
doi:10.1371/journal.pone.0130754.t005
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The risk allele frequency was lower in the Pakistani group for 13 SNPs and higher for three
SNPs compared to NPHSII.
The 19 and 13 SNP GSs were calculated for both Pakistani studies and the results are shown
in Table 4. For the 19 SNP GS, full genotyping was available for 304 samples (119 controls/175
cases) in the Islamabad study and for 438 samples (130 controls/308 cases) in the Lahore study.
For the 13 SNP GS, full genotyping was available for 317 samples (123 controls/194 cases) in
the Islamabad study and for 490 samples (145 controls/345 cases) in the Lahore study. In the
Islamabad sample, a statistically significant increase in the mean gene score was observed
between cases and controls for the 13 SNP GS (p = 0.04), but not for the 19 SNP GS (p = 0.35).
For the Lahore sample, the mean gene score was not statistically significantly different between
cases and controls for either score (19 SNP GS p = 0.75, 13 SNP GS p = 0.95). The 19 and 13
SNP GSs were found to be lower in the controls compared to those in NPHSII who did not go
on to develop CHD in both the Islamabad (19 SNP GS p = 2.92 x10-14, 13 SNP GS p = 5.62x10-
6) and the Lahore cohorts (19 SNP GS p = 7.78 x10-13, 13 SNP GS p = 1.49x10-9).
While the higher quintiles of the 13 SNP GS gene score appear to have a greater odds ratio
for outcome compared to the bottom quintile in the Islamabad sample, this was not statistically
significant. No trend between quintile of gene score and outcome was observed for the 19 SNP
GS in the Islamabad sample or for either GS in the Lahore sample (Fig 2 and S7 Table).
Discussion
The aim of including genetic information in CHD risk prediction is to identify those who have a
high overall risk but who would be classed as being at low or intermediate risk using conven-
tional risk factor scores. In this study, we found that a 19 SNP GS, which uses CHD risk weight-
ing from published meta-analyses, showed improved risk classification over and above the
Framingham score alone in NPHSII when those men who went up a risk category (for example
moving into the high risk category) were considered. The exclusion of six SNPs in non-CARDI-
oGRAMplusC4D loci had a modest detrimental effect on the utility of the gene score in the UK
men, reducing the overall NRI non-significantly from 4.5% to 3.0% with a similar non-signifi-
cant decrease in the number of men correctly reclassified into the high risk group. Thus the 19
SNP GS, appears to have the better utility. By contrast, in two case-control studies from Pakistan
the gene scores did not perform as well. While in the subjects from Islamabad the 13 SNP GS
showed a significant case-control effect, neither score showed utility in the samples from Lahore.
There are a number of potential reasons why the results from the European group were not
confirmed in Pakistanis. Firstly both Pakistani studies comprise only a few hundred samples
and thus sample size and statistical power is an issue. We estimated that should the same effect
found in NPHSII be present in the Pakistani group, to have 80% power to detect it (at the 5%
significance threshold), approximately 340 cases and approximately 340 controls would be
required for both gene scores. This is well above the number of individuals for whom complete
genotyping was available in both Pakistani studies. Secondly, “cases” were defined differently
in the two Pakistani studies. There was very little difference between the mean gene score in
cases and controls in the Lahore sample which used a much broader definition of CHD, com-
pared to the Islamabad group which used an MI phenotype (more like the “hard” endpoints
used in the prospective NPHSII). A further limitation of the study is that using retrospectively
collected cases restricts the case group to those who have survived which may introduce a sur-
vivor bias to the sample.
A further possibility is SNP selection. While eight of the SNPs are non-synonymous (and
thus are likely to be the functional), and the APOA5 promoter variant has been shown to be
directly functional [27] many are not in protein coding regions. It is possible that such SNPs
CHD Risk Prediction Gene Score in UK Men and the Pakistani Population
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merely “tag” the functional SNP located in the same linkage disequilibrium (LD) block. Given
the differing LD patterns between ethnicities, it is possible that some of the SNPs used here are
in strong LD with the functional SNP in Europeans but not in other ethnic groups. For exam-
ple, the SNPs rs599839 and rs646776 are often used to tag each other at the CELSR2-PSRC1--
SORT1 locus, with rs599839 being known to be functional [28]. Data from the HapMap
project [29] shows that the LD between the two SNPs is r2 = 0.95 in the Northern European
group and r2 = 0.76 in the Japanese group but the two SNPs are not in LD in the Yoruba group
(from Ibadan, Nigeria). However, a study of approximately 2000 Indians collected fromMum-
bai and Bangalore found the two SNPs to be in strong LD (r2 = 0.98) in this group. Further-
more, a number of SNPs at the 9p21 locus were genotyped in the PROMIS study of ethnic
Pakistanis living in the UK and the LD pattern was found to be similar to Europeans at this
locus [30] and a comparison of the genetic architecture of the LPA gene in individuals of
Fig 2. Association between gene score and outcome in the Pakistani samples. Logistic regression was performed for each group. (A) Islamabad study,
outcome is MI, and (B) Lahore study, outcome is CHD. Error bars represent 95% confidence intervals.
doi:10.1371/journal.pone.0130754.g002
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different ethnicities (including South Asians) living in Canada found similar haplotype blocks
to be present in the groups studied [31]. Therefore, for these loci we conclude that it is appro-
priate to use the SNP identified in studies with European participants. To what extent this can
be extrapolated to the other SNPs and loci included is not clear, and for example, a study of
CETP polymorphisms in the Punjabi population from Northern India found the LD pattern to
differ from that observed in Europeans[32] but overall information regarding LD patterns in
South Asians is limited. Moreover, given that the risk allele frequency is statistically signifi-
cantly lower for 13 of the 19 SNPs in the Pakistani group compared to NPHSII, it is unsurpris-
ing that the gene scores are also statistically significantly lower. This shows that even if many of
the SNPs are functional, then gene scores based on these SNPs will perform less well in the
Pakistani group. In order to optimise the use of the gene scores for use in those of South Asian
ethnicity, the functional SNP should be identified (bearing in mind that the functional SNP
may differ between ethnic groups) in all cases to maximise the performance of a gene score
based on this set of loci, and it may be necessary to design a South-Asian specific gene score.
We can only speculate whether the modest performance of the gene scores observed in Paki-
stani subjects here will be seen in samples from other parts of the Indian Subcontinent, as there
is considerable genetic diversity within the region and since score performance is in part
dependent on the frequency of the risk alleles. To date, allele frequency information across the
Indian Subcontinent is limited for the SNPs used. A small number of Punjabi subjects (n = 96)
from Lahore were genotyped as part of the 1000 genomes project (phase 3) [33]. No difference
in allele frequencies was observed for any of the SNPs in this data set when compared with the
control groups presented here. The risk allele frequency of the 9p21 SNPs genotyped in the
PROMIS study were statistically significantly higher than observed here [30]. While a similar
risk allele frequency to that found here was observed for rs662799 (in the APOA5 promoter) in
a Punjabi Pakistani case-control study, the risk allele frequency observed for rs599839 (at the
SORT1 locus) in that study was much lower than observed here [34]. Another factor which
may influence how representative the results presented here are, is that five of the 19 SNPs gen-
otyped in the Islamabad case-control study were not in Hardy-Weinberg equilibrium. In each
case this was due to an excess of homozygotes compared to what would be expected. This is
likely caused by the presence of population sub-structure[35]. Clearly much more data is
required from larger samples representative of different regions and groups from the Indian
Subcontinent to determine the frequencies of these SNPs.
Overall this work demonstrated that the use of a 19 SNP gene score has the potential to
improve risk stratification in European individuals over and above classical CHD risk factors.
Reducing the number of SNPs in the score to only the 13 with GWAS-proven effects on CHD
risk had a modest detrimental effect on the utility. We do not have definitive evidence of the util-
ity of either score in subjects from Pakistan and larger samples are required to determine this.
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